Clinical Trials Logo

Cancer, Treatment-Related clinical trials

View clinical trials related to Cancer, Treatment-Related.

Filter by:

NCT ID: NCT04634071 Recruiting - Smoking Cessation Clinical Trials

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

TTOP
Start date: January 12, 2021
Phase: Phase 2
Study type: Interventional

Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.

NCT ID: NCT03413865 Recruiting - Clinical trials for Cancer, Treatment-Related

Telemedicine Clinic for Prostate Cancer Patients

Start date: October 28, 2016
Phase: N/A
Study type: Interventional

This randomized, open label study will evaluate a nurse and pharmacist led clinic conducted remotely from Grand River Regional Cancer Centre at Grand River Hospital (GRRCC/GRH) using OTN teleconferencing as a platform for patients with prostate cancer receiving oral chemotherapy agents.

NCT ID: NCT03199300 Recruiting - Clinical trials for Cardiovascular Morbidity

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

InvestiCAT
Start date: December 12, 2017
Phase:
Study type: Observational

Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.